Show simple item record

dc.contributor.authorChaturvedi, Santosh K
dc.contributor.authorMaguire, Peter
dc.date.accessioned2010-02-12T11:25:25Z
dc.date.available2010-02-12T11:25:25Z
dc.date.issued1998-09
dc.identifier.citationPersistent somatization in cancer: a controlled follow-up study. 1998, 45 (3):249-56 J Psychosom Resen
dc.identifier.issn0022-3999
dc.identifier.pmid9776370
dc.identifier.doi10.1016/S0022-3999(98)00013-0
dc.identifier.urihttp://hdl.handle.net/10541/91951
dc.description.abstractNature and frequency of somatic complaints, severity of anxiety and depression, and nature of psychiatric symptoms and disorders were evaluated in 81 adequately treated cancer patients, disease-free or with residual disease, using a controlled, prospective follow-up design. Patients were included in the index group (n=60) if they had persistent somatic complaints or unexplained nature or severity of somatic complaints, or the control group (n=21), if they did not report somatic complaints. Instruments used for evaluation were the Scale for Assessment of Somatic Symptoms, Hospital Anxiety and Depression Scale, Psychiatric Assessment Schedule, and DSM-III-R. Common somatic complaints in the index group were pain (19%), fatigue (17%), sensory symptoms (30%), and mixed symptoms (27%). Subjects in the index group significantly (p<0.001) more often had depressive or anxiety disorder (19%) and atypical somatoform disorder (15%). Patients were treated appropriately with psychotropic medications and counseling. Follow-up at 4-6 months revealed a significant reduction in the number of somatic symptoms (p<0.001) and anxiety (p<0.001) and depression (p<0.05) scores. The observations confirm that somatic symptoms may persist in cancer patients, which are related to concomitant psychopathology, and require psychiatric intervention.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshDepressive Disorder
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshPain
dc.subject.meshProspective Studies
dc.subject.meshPsychiatric Status Rating Scales
dc.subject.meshSeverity of Illness Index
dc.subject.meshSomatoform Disorders
dc.titlePersistent somatization in cancer: a controlled follow-up study.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Psychological Medicine Group, Christie Hospital, Manchester, UK. chatur@nimhans.ren.nic.inen
dc.identifier.journalJournal of Psychosomatic Researchen
html.description.abstractNature and frequency of somatic complaints, severity of anxiety and depression, and nature of psychiatric symptoms and disorders were evaluated in 81 adequately treated cancer patients, disease-free or with residual disease, using a controlled, prospective follow-up design. Patients were included in the index group (n=60) if they had persistent somatic complaints or unexplained nature or severity of somatic complaints, or the control group (n=21), if they did not report somatic complaints. Instruments used for evaluation were the Scale for Assessment of Somatic Symptoms, Hospital Anxiety and Depression Scale, Psychiatric Assessment Schedule, and DSM-III-R. Common somatic complaints in the index group were pain (19%), fatigue (17%), sensory symptoms (30%), and mixed symptoms (27%). Subjects in the index group significantly (p<0.001) more often had depressive or anxiety disorder (19%) and atypical somatoform disorder (15%). Patients were treated appropriately with psychotropic medications and counseling. Follow-up at 4-6 months revealed a significant reduction in the number of somatic symptoms (p<0.001) and anxiety (p<0.001) and depression (p<0.05) scores. The observations confirm that somatic symptoms may persist in cancer patients, which are related to concomitant psychopathology, and require psychiatric intervention.


Files in this item

This item appears in the following Collection(s)

Show simple item record